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Objective: Guidelines to screen and monitor schizophrenic patients 
treated with antipsychotics for diabetes were recently proposed 
by the ADA. Preliminary evidence however suggests that 
the use of these guidelines may result in a large underdiagnosis of 
glucose abnormalities in high risk groups such as patients diagnosed 
with schizophrenia. Nevertheless, early detection of glucose 
abnormalities could well be of eminent importance in patients 
with schizophrenia, as prediabetic abnormalities and even frank 
diabetes are shown to be potentially reversible in this specific population, 
in contrast to classical type 2 diabetes, where a progressive 
deterioration of the insulin producing beta-cell occurs despite the 
use of initially effective antidiabetic therapies. The aim of the current 
study was to assess the presence of diabetes in schizophrenic 
patients, to investigate the adequacy of the current screening 
guidelines for the detection of diabetes in patients with schizophrenia, 
and to assess potential improvements of these guidelines. 
Methods: 415 patients, who were on stable medication for 
at least three months, entered a prospective metabolic follow-up 
program, with a baseline screening consisting of a full laboratory 
screening and a 75 g Oral Glucose Tolerance Test (OGTT). The 
screening took place over a period of two years, and patients 
were not known with diabetes prior to the baseline screening. At 
baseline, the sensitivity of two screening strategies for diabetes 
was compared to the ‘Gold Standard’ for the detection of diabetes, 
namely performing an OGTT in all patients. The two strategies 
were: 1) the current screening guideline of assessing fasting 
glucose in all patients and 2) a screening strategy derived from 
the guidelines of the WHO of first assessing fasting glucose in all 
patients, and in those patients with fasting glucose>100 mg/dl, 
subsequently performing an OGTT. 
Results: In the total sample, 6.3% (n = 26) met criteria for 
diabetes. Another 23.4% (n = 97) showed prediabetic abnormalities. 
A screening based on the consensus guidelines detected 
diabetes in 12 patients (2.9%). However, these 12 diabetes cases 
only represented 46.2% of the 26 cases identified by means of 
an OGTT. The WHO derived two-step strategy of performing an 
OGTT in patients presenting with IFG would have detected 96.2% 
of diabetes cases (25 out of 26 cases). 
Conclusion: These data confirm that metabolic abnormalities 
are highly prevalent in schizophrenic patients treated with antipsychotics, 
certainly when taking into account that all patients 
that were screened were not diagnosed with diabetes prior to 
the baseline screening, so that the diagnosed cases are newly 
detected or incidence cases. As the screening was performed over 
the period of two years, the current data suggest a mean annual 
incidence of diabetes of 3.15% (6.3% incident cases/2 years), or 
almost 14 times higher than the estimated annual incidence for 
the Belgian general population. The guidelines as proposed by 
the ADA, did not sufficiently detect diabetes in this specific high 
risk group. The alternative two-step strategy was able to detect the 
vast majority of diabetes cases and should therefore be considered 
in the clinical routine of screening and monitoring patients with 
schizophrenia. 
 
